文献速递消化系统肿瘤

RAS与BRAF野生型转移性结直肠癌对一线西妥昔单抗联合伊立替康获得性耐药后再次挑战治疗:一项2期单臂临床试验

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
PubMed 文献 · JAMA Oncol · 2019-01-01

这项多中心2期单臂试验评估西妥昔单抗联合伊立替康三线治疗RAS与BRAF野生型mCRC的活性,28例患者客观缓解率21%(95%CI 10%-40%),疾病控制率54%(95%CI 36%-70%),达到主要终点;ctDNA RAS野生型者无进展生存期显著更长(4.0 vs 1.9个月;HR 0.44;95%CI 0.18-0.98;P=0.03)。

要点

  • RAS与BRAF野生型mCRC再次挑战西妥昔单抗联合伊立替康的缓解率为21%(95%CI 10%-40%),达到主要终点。
  • 再次挑战基线ctDNA可评估患者中48%(12/25)检出RAS突变,确认部分缓解者均未检出RAS突变。
  • ctDNA RAS野生型者中位PFS 4.0个月,RAS突变型者1.9个月(HR 0.44;95%CI 0.18-0.98;P=0.03)。

核心结论

  • 这是首个前瞻性证据表明,对一线伊立替康联合西妥昔单抗方案获得性耐药的RAS与BRAF野生型mCRC患者,西妥昔单抗联合伊立替康再次挑战策略可能有效。
  • 作者认为,评估ctDNA的RAS突变状态可能有助于筛选候选患者。

研究设计与样本

  • 多中心2期单臂试验,2015年1月7日至2017年6月19日开展,共纳入28例患者(9例女性,19例男性;中位年龄69岁,范围45-79岁)。
  • 主要入组标准包括组织样本为RAS与BRAF野生型;既往一线含伊立替康和西妥昔单抗方案至少达部分缓解、一线治疗无进展生存期至少6个月且末次西妥昔单抗给药后4周内进展;既往接受过二线含奥沙利铂和贝伐珠单抗治疗。
  • 干预为每两周西妥昔单抗500 mg/m2联合伊立替康180 mg/m2;基线采集液体活检分析ctDNA。
  • 主要终点为按实体瘤疗效评价标准1.1版评估的客观缓解率;次要终点包括无进展生存期和总生存期,探索性分析为ctDNA的RAS突变。

主要发现

  • 6例部分缓解(其中4例确认)和9例疾病稳定(缓解率21%;95%CI 10%-40%;疾病控制率54%;95%CI 36%-70%)。
  • 主要终点达到,因缓解率95%CI下限高于5%。
  • 再次挑战基线ctDNA可评估的25例患者中12例(48%)检出RAS突变;达到确认部分缓解的患者样本中未检出RAS突变。
  • ctDNA RAS野生型患者的中位无进展生存期显著长于RAS突变型患者(4.0 vs 1.9个月;风险比0.44;95%CI 0.18-0.98;P=0.03)。

关键数值与推荐

  • 客观缓解率21%(95%CI 10%-40%),疾病控制率54%(95%CI 36%-70%)。
  • ctDNA RAS野生型 vs RAS突变型中位无进展生存期4.0 vs 1.9个月(HR 0.44;95%CI 0.18-0.98;P=0.03)。
  • 再次挑战基线ctDNA RAS突变检出率48%(12/25)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Based on a small retrospective study, rechallenge with cetuximab-based therapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC) who were previously treated with the same anti-epidermal growth factor receptor-based regimen might be efficacious. Recent data suggest the role of liquid biopsy as a tool to track molecular events in circulating tumor DNA (ctDNA). OBJECTIVE: To prospectively assess the activity of cetuximab plus irinotecan as third-line treatment for patients with RAS and BRAF wild-type mCRC who were initially sensitive to and then resistant to first-line irinotecan- and cetuximab-based therapy. DESIGN, SETTING, AND PARTICIPANTS: Multicenter phase 2 single-arm trial conducted from January 7, 2015, to June 19, 2017. Liquid biopsies for analysis of ctDNA were collected at baseline. Main eligibility criteria included RAS and BRAF wild-type status on tissue samples; prior first-line irinotecan- and cetuximab-based regimen with at least partial response, progression-free survival of at least 6 months with first-line therapy, and progression within 4 weeks after last dose of cetuximab; and prior second-line oxaliplatin- and bevacizumab-based treatment. INTERVENTIONS: Biweekly cetuximab, 500 mg/m2, plus irinotecan, 180 mg/m2. MAIN OUTCOMES AND MEASURES: Overall response rate according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included progression-free survival and overall survival and, as an exploratory analysis, RAS mutations in ctDNA. RESULTS: Twenty-eight patients (9 women and 19 men; median age, 69 years [range, 45-79 years]) were enrolled. Six partial responses (4 confirmed) and 9 disease stabilizations were reported (response rate, 21%; 95% CI, 10%-40%; disease control rate, 54%; 95% CI, 36%-70%). Primary end point was met because lower limit of 95% CI of response rate was higher than 5%. RAS mutations were found in ctDNA collected at rechallenge baseline in 12 of 25 evaluable patients (48%). No RAS mutations were detected in samples from patients who achieved confirmed partial response. Patients with RAS wild-type ctDNA had significantly longer progression-free survival than those with RAS mutated ctDNA (median progression-free survival, 4.0 vs 1.9 months; hazard ratio, 0.44; 95% CI, 0.18-0.98; P = .03). CONCLUSIONS AND RELEVANCE: This is the first prospective demonstration that a rechallenge strategy with cetuximab and irinotecan may be active in patients with RAS and BRAF wild-type mCRC with acquired resistance to first-line irinotecan- and cetuximab-based therapy. The evaluation of RAS mutational status on ctDNA might be helpful in selecting candidate patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02296203.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Cremolini C, Rossini D, Dell'Aquila E, et al. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA Oncol. 2019. PMID: 30476968. doi:10.1001/jamaoncol.2018.5080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。